Professor ANDREW BACON's Outputs (2)

Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020 (2024)
Journal Article
Liu, H., Stanworth, S. J., McPhail, S., Bishton, M., Rous, B., Bacon, A., & Coats, T. (2024). Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020. Blood Advances, 8(17), 4593-4605. https://doi.org/10.1182/bloodadvances.2024013102

We report 1- and 5-year survival following AML diagnosis and early mortality, within 30 days of systemic anti-cancer therapy (SACT) treatments, using national cancer registry data in England.

Patients aged 18-99 years diagnosed between 2013 and 2... Read More about Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020.

Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019 (2022)
Journal Article
Liu, H., Stiller, C. A., Crooks, C. J., Rous, B., Bythell, M., Broggio, J., Rankin, J., Nanduri, V., Lanyon, P., Card, T. R., Ban, L., Elliss-Brookes, L., Broughan, J. M., Paley, L., Wong, K., Bacon, A., Bishton, M., & West, J. (2022). Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019. British Journal of Haematology, 199(5), 728-738. https://doi.org/10.1111/bjh.18459

This analysis is the largest population-based study to date to provide contemporary and comprehensive epidemiological estimates of all third edition of the International Classification of Diseases for Oncology (ICD-O-3) coded Langerhans cell histiocy... Read More about Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–2019.